Physician profile
Sofia Naz Ahmad
NPI 1336599604
$3,445.62
in general payments reported to CMS, 2019-2025
15 companies · $551 in 2025
The $551 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $221 · 2022: $78.38 · 2023: $389 · 2024: $1,694 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504 · Travel and Lodging: $990 · Entertainment: $133 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.89 |
| Travel and Lodging | $989.65 |
| Entertainment | $133.14 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,458.57 | 2019-2024 | Acuvue |
| Alcon Vision LLC | $276.78 | 2023-2024 | Total30, Precision 1, Dailies Total1 |
| Glaukos Corporation | $181.88 | 2025 | Photrexa Viscous and Photrexa |
| Optos, INC. | $176.44 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $152.47 | 2020-2023 | Cequa |
| Rxsight INC | $145.29 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $133.95 | 2025 | Infuse |
| Abb Con-Cise Optical Group LLC | $130.01 | 2024 | Contact Lens, Spectacle Lenses |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $122.03 | 2025 | Xdemvy |
| Dompe US, INC. | $121.81 | 2023 | Oxervate |
| Shire North American Group INC | $121.66 | 2019 | |
| Maculogix, INC. | $117.92 | 2020 | |
| Harrow Eye, LLC | $113.51 | 2025 | Vevye |
| Coopervision INC. | $68.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.